{"nctId":"NCT00332241","briefTitle":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","startDateStruct":{"date":"2006-06"},"conditions":["Autistic Disorder"],"count":98,"armGroups":[{"label":"A1","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"A2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aripiprazole","otherNames":["Abilify"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meets current Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition (DSM-IV) diagnostic criteria for AD and demonstrates serious behavioral problems. Diagnosis confirmed by Autism Diagnostic Interview- Revised (ADI-R)\n* CGI score \\> = 4 AND and Aberrant Behavior Checklist (ABC) Irritability/Agitation subscale score \\> = 18 at screening and baseline (randomization)\n* Mental age of at least 18 months\n* Male or female 6 to 17 years of age, inclusive, at the time of randomization\n\nExclusion Criteria:\n\n* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each.\n* Patients previously treated and not responding to aripiprazole treatment\n* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder\n* Current diagnosis of bipolar disorder, psychosis, or schizophrenia, or major depression\n* A seizure in the past year\n* History of severe head trauma or stroke\n* Patients undergoing non-pharmacologic therapies (e.g., psychotherapy, behavioral modification) must have started at least 2 months prior to the initial screening visit and must remain in a consistent treatment program for the duration of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score","description":"The ABC is a 58-item informant-based assessment of problem behaviors in children/adolescents with mental retardation. Items are rated on a 4-point scale (0=no problem, 3=severe problem), and resolve into 5 domain subscales. A decrease in score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"1.43"},{"groupId":"OG001","value":"-12.9","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Mean Clinical Global Impressions Improvement Scale (CGI-I) Score","description":"The CGI scale is a clinician-rated global assessment of a patient's improvement over time. Baseline assessment rated a patient's condition on a 7-point scale (1=no symptoms, 7=very severe symptoms). Subsequent assessed improvement relative to baseline symptoms on a 7-point CGI-I item scale (1=very much improved, 7=very much worse).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.18"},{"groupId":"OG001","value":"2.2","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Response at Week 8","description":"Response defined as a â‰¥ 25% reduction from baseline to endpoint in the ABC Irritability Subscale score and a CGI-I score of 1 or 2 at endpoint","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)","description":"CY-BOCS=10-item assessment of obsessive-compulsive symptoms in patients \\<18 years. 5 items pertaining to compulsions rate symptoms (time spent, interference with functioning, distress, resistance, control) on a 5-point scale (0=no symptoms/minimum severity, 4=extreme symptoms/maximum severity). A decrease in value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.52"},{"groupId":"OG001","value":"-3.8","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores","description":"Mean change (Week 8 - baseline) in the other ABC subscale scores (lethargy/social withdrawal; stereotypic behavior; hyperactivity/ noncompliance; inappropriate speech). A decrease in value indicates improvement","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.5"},{"groupId":"OG001","value":"-12.7","spread":"1.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"0.62"},{"groupId":"OG001","value":"-4.8","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.39"},{"groupId":"OG001","value":"-2.5","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"1.13"},{"groupId":"OG001","value":"-7.9","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)","description":"A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=no symptoms; 7=very severe symptoms). The patient's improvement relative to the symptoms at baseline on were assessed on a 7-point CGI-I (1=very much improved; 7=very much worse). A decrease in value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.15"},{"groupId":"OG001","value":"-1.2","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Summary of Safety","description":"Deaths, Adverse Events (AEs), Serious AEs (SAEs), Treatment-Emergent AEs and AEs leading to discontinuation","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Adjusted mean change (Week 8 - baseline) in body weight","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.29"},{"groupId":"OG001","value":"2.0","spread":"0.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["INCREASED APPETITE","FATIGUE","HEADACHE","SOMNOLENCE","VOMITING"]}}}